Table 2.
Pharmacological treatment irritable bowel syndrome-C studies and clinical efficacy during last 5 years
| Category/No. of studies/Ref. | n | vs Placebo | Abdominal distention/pain | QOL/patient satisfaction/global improvement | Stool consistency/bowel habits | Recommendation vs placebo |
| 5-HT3 antagonists | ||||||
| Alosetron, cilansetron/4 | ||||||
| Cremonini et al[79] 2012 | 705 | Yes | - | SS | - | Superior |
| Rahimi et al[80] 2008 | 4.17 | Yes | SS | SS | - | Superior |
| Metanalysis | ||||||
| Andresen et al[81] 2008 | 7487 Metanalysis | Yes or mebeverine | SS | SS | - | Superior |
| Ford et al[82] 2009 | 7216 | Yes | SS | SS | - | Superior |
| Metanalysis | ||||||
| Ramosetron/3 | ||||||
| Matsueda et al[85] 2008 | 418 | Yes | SS (5/10 μg) | SS (5/10 μg) | - | Superior |
| Matsueda et al[86] 2008 | 539 | Yes | SS (5 μg) | SS (5 μg) | SS (5 μg) | Superior |
| Lee et al[87] 2011 | 343 | Mebeverine | NS(5 μg) | NS (5 μg) | NS(5 μg) | Equal |
| 135 mg t.i.d | ||||||
| LX-1031/1 | ||||||
| Brown et al[92] 2011 | 155 | Yes | SS only the 1st week (1000 mg 4 times/d) | - | SS (1000 mg 4 times/d) | Superior |
| Crofelemer/1 | ||||||
| Angel et al[94] 2008 | 246 | Yes | SS 500 mg b.i.d | SS | SS | Superior |
| Antibiotics | ||||||
| Rifaximin/2 | ||||||
| Pimentel et al[105] 2011 | 1260 | Yes | SS | SS | SS | Superior |
| Menees et al[106] 2012 | 1803 | Yes | SS | SS | - | Superior |
| Metanalysis | ||||||
| 5ASA compounds, mesalazine/3 | ||||||
| Corinaldesi et al[108] 2009 | 20 | Yes | NS | SS | NS | Equal |
| Andrews et al[109] 2011 | 12 | No | SS | SS | - | - |
| Comparison to baseline | ||||||
| Tuteja et al[110] 2012 | 17 | Yes | NS | NS | NS | Equal |
QOL: Quality of life; ASA: Aminosalicylic acid; SS: Statistically significant; NS: Not significant.